Subgroup analysis of the MCL-002 (SPRINT) trial of lenalidomide in relapsed/refractory MCL

At the 20th Congress of the European Hematology Association (EHA), Marek Trněný, MD, PhD, of Charles University, Prague, Czech Republic, discusses the results of the subgroup analysis of the phase 2 multicentre, randomised, open-label MCL-002 (SPRINT) study of lenalidomide, an immunomodulator with antineoplastic and antiproliferative effects, versus investigator’s choice (chlorambucil, cytarabine, fludarabine, gemcitabine, or rituximab) in patients with relapsed/refractory mantle cell lymphoma (MCL).

Year of Production:
Running Time:
Color/Sound:

2015
02:57
Color/Sound

Comments are closed.